Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pevonedistat with Decitabine and Cedazuridine in Higher-Risk MDS
NCT04985656Phase 2Withdrawn
- Sponsor
- Takeda
- Start
- Oct 2021
- Primary completion
- Jan 2024
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of pevonedistat in myelodysplastic syndrome (MDS), sponsored by Takeda. Planned start Oct 2021; status: withdrawn.
02
Drugs
pevonedistat
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT04985656.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04985656.